Top

Osteoporosis International

Published in:

01-10-2007 | Original Article

Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study

Authors: J. Prior, D. Burdge, E. Maan, R. Milner, C. Hankins, M. Klein, S. Walmsley

Published in: Osteoporosis International | Issue 10/2007

Abstract

Summary

This Canadian study of bone health showed that HIV+ women were more likely to have had fragility fractures (OR 1.7) but had BMD values that were not different than women from a national population-based cohort.

Introduction

Given that 17.5 million women globally are HIV-infected and living longer on anti-retroviral therapy (ART+), it is essential to determine whether they are at risk for osteoporosis as is currently assumed.

Methods

Assessment of osteoporosis risk factors and lifetime low-trauma (fragility) fracture history used a common interviewer-administered questionnaire and phantom-adjusted bone mineral density (BMD). This study compared HIV+ Canadian women with age- and region-matched control women (1:3) from a national population-based study of osteoporosis.

Results

One hundred and thirty-eight HIV+ women (100 ART+, 38 ART-) were compared with 402 controls. There were no differences in age (37.7 vs. 38.0 years), BMI (25.0 vs. 26.2), family history of osteoporosis, exercise history, alcohol or calcium intakes, age at menarche, oral contraceptive use or parity. HIV+ cases included more Aboriginal and Black women (12.5% and 16.2 vs. 2% and 1%, respectively), smoked and used injection drugs (53%) more, were more often treated with glucocorticoids, had oligomenorrhea, and reported 10-kg weight cycling. Significantly more HIV+ women reported lifetime fragility fractures (26.1% vs. 17.3; OR 1.7, 95% CI 1.1, 2.6). HIV+ and control women did not differ in BMD: spine 1.0 ± 0.12 vs.1.0 ± 0.14 g/cm² (diff. 0.0, 95% CI −0.27, 0.27) or total femur 0.91 ± 0.15 vs. 0.93 ± 0.12 g/cm² (diff 0.02, 95% CI +0.005, −0.045).

Conclusion

HIV+ women reported significantly more past osteoporotic fractures than population-based controls despite normal BMD. Research is needed to assess bone microarchitecture and develop a reliable fracture risk assessment tool for HIV+ women.

Thomas J, Doherty SM (2003) HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr 33(3):281–291PubMed

Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, Amorico G et al (2001) Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15(1):137–138PubMedCrossRef

Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S (2004) Reduced bone density in HIV-infected women. AIDS 18(3):475–483PubMedCrossRef

Stephens EA, Das R, Madge S, Barter J, Johnson MA (1999) Symptomatic osteoporosis in two young HIV-positive African women. AIDS 13(18):2605–2606PubMedCrossRef

McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M et al (2004) Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic.Ill.) 3(3):86–91CrossRef

Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M et al (2005) Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos.Int published on-line March 2005

Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F et al (2004) Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48(1):39–48PubMed

Martin K, Lawson-Ayayi S, Miremont-Salame G, Blaizeau MJ, Balestre E, Lacoste D et al (2004) Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999–2002). HIV Med 5(6):421–426PubMedCrossRef

Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17(13):1917–1923PubMedCrossRef

10.

Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Prior JC et al (2000) Estimation of prevalence of low bone density in Canadian women and men using a population-specific DEXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 11:897–904PubMedCrossRef

11.

Loiseau-Peres S, Delaunay C, Poupon S, Lespessailles E, Ballouche N, Arsac P et al (2002) Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine 69(5):482–485PubMedCrossRef

12.

O’Neil TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ et al (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Mineral Res 11:1010–1018CrossRef

13.

Hankins C, Lapointe N, Walmsley S (1998) Participation in clinical trials among women living with HIV in Canada. Canadian Women’s HIV Study Group. CMAJ 159(11):1359–1365PubMed

14.

Kreiger N, Tenenhouse A, Joseph L, Mackenzie MD, Poliquin S, Brown JP et al (1999) The Canadian Multicentre Osteoporosis Study (CaMos): Background, rationale, methods. Can J Aging 18:376–387

15.

Archibald, C. HIV/AIDS EPI Updates. http://www.phac-aspc.gc.ca. 1-13-2006. Ref Type: Electronic Citation

16.

Pearson D, Cawte SA, Green DJ (2002) A comparison of phantoms for cross-calibration of lumbar spine DXA. Osteoporos Int 13(12):948–954PubMedCrossRef

17.

Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T (2004) Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: The Penn State Young Women’s Health Study. Bone 35(3):750–759PubMedCrossRef

18.

Luckey MM, Wallenstein S, Lapinski R, Meier DE (1996) A prospective study of bone loss in African-American and White women-a clinical research center study. J Clin Endocrinol Metab 81:2948–2956PubMedCrossRef

19.

Sowers M, Randolph JF, Crutchfield M, Jannausch ML, Shapiro B, Zhang B et al (1998) Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Min Res 13(7):1191–1202CrossRef

20.

Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227PubMedCrossRef

21.

Sioban H, Schuman P, Cohen M, Ohmit SE, Cu-Uvin S, Lin X et al (2000) Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 24:68–75

22.

Money DM, Arikan YY, Remple V, Sherlock C, Craib K, Birch P et al (2003) Genital tract and plasma human immunodeficiency virus viral load throughout the menstrual cycle in women who are infected with ovulatory human immunodeficiency virus. Am J Obstet Gynecol 188(1):122–128PubMedCrossRef

23.

Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Benson C (2001) Frequency of anovulation and early menopause among women enrolled in selected adult aids clinical trials group studies. JID 184:1325–1327PubMedCrossRef

24.

Swain MC, Bulbrook RD, Hayward JL (1974) Ovulatory failure in a normal population and in patients with breast cancer. J Obstet Gynaecol Br Commonw 81(8):640–643PubMed

25.

Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC (1994) Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 96:521–530PubMedCrossRef

Title: Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study
Authors: J. Prior
D. Burdge
E. Maan
R. Milner
C. Hankins
M. Klein
S. Walmsley
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0428-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2007

Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world

Simple, novel physical activity maintains proximal femur bone mineral density, and improves muscle strength and balance in sedentary, postmenopausal Caucasian women

Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate

Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study

Homocysteine and fracture risk in postmenopausal women: the OFELY study

Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005